291 related articles for article (PubMed ID: 33691361)
21. Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study.
Lo Iacono M; Monica V; Righi L; Grosso F; Libener R; Vatrano S; Bironzo P; Novello S; Musmeci L; Volante M; Papotti M; Scagliotti GV
J Thorac Oncol; 2015 Mar; 10(3):492-9. PubMed ID: 25514803
[TBL] [Abstract][Full Text] [Related]
22. The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study.
Zauderer MG; Martin A; Egger J; Rizvi H; Offin M; Rimner A; Adusumilli PS; Rusch VW; Kris MG; Sauter JL; Ladanyi M; Shen R
Lancet Digit Health; 2021 Sep; 3(9):e565-e576. PubMed ID: 34332931
[TBL] [Abstract][Full Text] [Related]
23. Metabolic rewiring and redox alterations in malignant pleural mesothelioma.
Urso L; Cavallari I; Sharova E; Ciccarese F; Pasello G; Ciminale V
Br J Cancer; 2020 Jan; 122(1):52-61. PubMed ID: 31819191
[TBL] [Abstract][Full Text] [Related]
24. Integrative Molecular Characterization of Malignant Pleural Mesothelioma.
Hmeljak J; Sanchez-Vega F; Hoadley KA; Shih J; Stewart C; Heiman D; Tarpey P; Danilova L; Drill E; Gibb EA; Bowlby R; Kanchi R; Osmanbeyoglu HU; Sekido Y; Takeshita J; Newton Y; Graim K; Gupta M; Gay CM; Diao L; Gibbs DL; Thorsson V; Iype L; Kantheti H; Severson DT; Ravegnini G; Desmeules P; Jungbluth AA; Travis WD; Dacic S; Chirieac LR; Galateau-Sallé F; Fujimoto J; Husain AN; Silveira HC; Rusch VW; Rintoul RC; Pass H; Kindler H; Zauderer MG; Kwiatkowski DJ; Bueno R; Tsao AS; Creaney J; Lichtenberg T; Leraas K; Bowen J; ; Felau I; Zenklusen JC; Akbani R; Cherniack AD; Byers LA; Noble MS; Fletcher JA; Robertson AG; Shen R; Aburatani H; Robinson BW; Campbell P; Ladanyi M
Cancer Discov; 2018 Dec; 8(12):1548-1565. PubMed ID: 30322867
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations.
Bueno R; Stawiski EW; Goldstein LD; Durinck S; De Rienzo A; Modrusan Z; Gnad F; Nguyen TT; Jaiswal BS; Chirieac LR; Sciaranghella D; Dao N; Gustafson CE; Munir KJ; Hackney JA; Chaudhuri A; Gupta R; Guillory J; Toy K; Ha C; Chen YJ; Stinson J; Chaudhuri S; Zhang N; Wu TD; Sugarbaker DJ; de Sauvage FJ; Richards WG; Seshagiri S
Nat Genet; 2016 Apr; 48(4):407-16. PubMed ID: 26928227
[TBL] [Abstract][Full Text] [Related]
26. Driver Gene and Novel Mutations in Asbestos-Exposed Lung Adenocarcinoma and Malignant Mesothelioma Detected by Exome Sequencing.
Mäki-Nevala S; Sarhadi VK; Knuuttila A; Scheinin I; Ellonen P; Lagström S; Rönty M; Kettunen E; Husgafvel-Pursiainen K; Wolff H; Knuutila S
Lung; 2016 Feb; 194(1):125-35. PubMed ID: 26463840
[TBL] [Abstract][Full Text] [Related]
27. IL-7 is expressed in malignant mesothelioma and has a prognostic value.
Mai HL; Deshayes S; Nguyen TV; Dehame V; Chéné AL; Brouard S; Blanquart C
Mol Oncol; 2022 Oct; 16(20):3606-3619. PubMed ID: 36054746
[TBL] [Abstract][Full Text] [Related]
28. Genes and Pathways Involved in the Progression of Malignant Pleural Mesothelioma: A Meta-analysis of Genome-Wide Expression Studies.
Mejia-Garcia A; Bonilla DA; Ramirez CM; Escobar-Díaz FA; Combita AL; Forero DA; Orozco C
Biochem Genet; 2024 Feb; 62(1):352-370. PubMed ID: 37347449
[TBL] [Abstract][Full Text] [Related]
29. KIAA0101 in Malignant Pleural Mesothelioma: A Potential Diagnostic and Prognostic Marker.
Lin P; Zhao Y; Li X; Liang Z
Comb Chem High Throughput Screen; 2022; 25(9):1498-1506. PubMed ID: 34238152
[TBL] [Abstract][Full Text] [Related]
30. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.
Guo G; Chmielecki J; Goparaju C; Heguy A; Dolgalev I; Carbone M; Seepo S; Meyerson M; Pass HI
Cancer Res; 2015 Jan; 75(2):264-9. PubMed ID: 25488749
[TBL] [Abstract][Full Text] [Related]
31. BRCA1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective Study.
Righi L; Duregon E; Vatrano S; Izzo S; Giorcelli J; Rondón-Lagos M; Ascoli V; Ruffini E; Ventura L; Volante M; Papotti M; Scagliotti GV
J Thorac Oncol; 2016 Nov; 11(11):2006-2017. PubMed ID: 27422796
[TBL] [Abstract][Full Text] [Related]
32. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
[TBL] [Abstract][Full Text] [Related]
33. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C
Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
[TBL] [Abstract][Full Text] [Related]
34. [Prognostic significance and immune cell infiltration analysis of differentially expressed genes in malignant pleural mesothelioma].
Wang N; Zhao QN; Yuan Q; Zhu BL; Wu W
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2023 Sep; 41(9):641-647. PubMed ID: 37805421
[No Abstract] [Full Text] [Related]
35. POLD1 Is Required for Cell Cycle Progression by Overcoming DNA Damage in Malignant Pleural Mesothelioma.
Shimizu D; Ishibashi M; Yamada T; Toda Y; Hosogi S; Ashihara E
Cancer Genomics Proteomics; 2024; 21(2):158-165. PubMed ID: 38423601
[TBL] [Abstract][Full Text] [Related]
36. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
McGregor SM; McElherne J; Minor A; Keller-Ramey J; Dunning R; Husain AN; Vigneswaran W; Fitzpatrick C; Krausz T
Hum Pathol; 2017 Feb; 60():86-94. PubMed ID: 27771374
[TBL] [Abstract][Full Text] [Related]
37. Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape.
Dagogo-Jack I; Madison RW; Lennerz JK; Chen KT; Hopkins JF; Schrock AB; Ritterhouse LL; Lester A; Wharton KA; Mino-Kenudson M; Danziger N; Hung YP; Mata DA; Ross JS
JCO Precis Oncol; 2022 Jun; 6():e2100422. PubMed ID: 35704798
[TBL] [Abstract][Full Text] [Related]
38. Fluorescence in situ hybridization detection of chromosome 22 monosomy in pleural effusion cytology for the diagnosis of mesothelioma.
Kinoshita Y; Hamasaki M; Matsumoto S; Yoshimura M; Sato A; Tsujimura T; Kamei T; Kawahara K; Iwasaki A; Nabeshima K
Cancer Cytopathol; 2021 Jul; 129(7):526-536. PubMed ID: 33493384
[TBL] [Abstract][Full Text] [Related]
39. Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications.
Suraokar MB; Nunez MI; Diao L; Chow CW; Kim D; Behrens C; Lin H; Lee S; Raso G; Moran C; Rice D; Mehran R; Lee JJ; Pass HI; Wang J; Momin AA; James BP; Corvalan A; Coombes K; Tsao A; Wistuba II
Ann Oncol; 2014 Jun; 25(6):1184-92. PubMed ID: 24669013
[TBL] [Abstract][Full Text] [Related]
40. Identification of glycolysis genes signature for predicting prognosis in malignant pleural mesothelioma by bioinformatics and machine learning.
Xiao Y; Huang W; Zhang L; Wang H
Front Endocrinol (Lausanne); 2022; 13():1056152. PubMed ID: 36523602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]